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Abstract
Background:  Gastric cancers frequently show chromosomal alterations which can cause
activation of oncogenes, and/or inactivation of tumour suppressor genes. In gastric cancer several
chromosomal regions are described to be frequently lost, but for most of the regions, no tumour
suppressor genes have been identified yet. The present study aimed to identify tumour suppressor
genes inactivated by nonsense mutation and deletion in gastric cancer by means of GINI (gene
identification by nonsense mediated decay inhibition) and whole genome copy number analysis.
Methods: Two non-commercial gastric cancer cell lines, GP202 and IPA220, were transfected
with siRNA directed against UPF1, to specifically inhibit the nonsense mediated decay (NMD)
pathway, and with siRNA directed against non-specific siRNA duplexes (CVII) as a control.
Microarray expression experiments were performed in triplicate on 4 × 44 K Agilent arrays by
hybridizing RNA from UPF1-transfected cells against non-specific CVII-transfected cells. In addition,
array CGH of the two cell lines was performed on 4 × 44K agilent arrays to obtain the DNA copy
number profiles. Mutation analysis of GINI candidates was performed by sequencing.
Results: UPF1 expression was reduced for >70% and >80% in the GP202 and IPA220 gastric
cancer cell lines, respectively. Integration of array CGH and microarray expression data provided
a list of 134 and 50 candidate genes inactivated by nonsense mutation and deletion for GP202 and
IPA220, respectively. We selected 12 candidate genes for mutation analysis. Of these, sequence
analysis was performed on 11 genes. One gene, PLA2G4A, showed a silent mutation, and in two
genes, CTSA and PTPRJ, missense mutations were detected. No nonsense mutations were detected
in any of the 11 genes tested.
Conclusion: Although UPF1 was substantially repressed, thus resulting in the inhibition of the
NMD system, we did not find genes inactivated by nonsense mutations. Our results show that the
GINI strategy leads to a high number of false positives.
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Background
As many other solid tumours, gastric cancer develops
through an accumulation of genetic and epigenetic altera-
tions. Although the knowledge of genetic and epigenetic
events occurring in gastric cancer is increasing, it is still far
from being complete.
Two major types of genetic instability are described in gas-
tric cancer, chromosomal instability and microsatellite
instability[1]. Chromosomal instable tumours show gross
chromosomal abnormalities leading to loss and or gain of
large genomic areas, while microsatellite instable tumours
show an increased mutation rate at the nucleotide level
and in general do not show gross chromosomal abnor-
malities. The majority of gastric cancers have a chromo-
somal instable phenotype and many studies have been
published describing frequent occurrence of chromo-
somal aberrations in gastric cancers [2-11]. Chromosomal
alterations can cause activation of oncogenes, by increas-
ing the copy number, and/or inactivation of tumour sup-
pressor genes, by loss of alleles. In case of tumour
suppressor genes, usually both alleles must be inactivated
in order to abrogate the function of a gene, which can be
achieved by any combination of loss, mutation, or pro-
moter hypermethylation. In gastric cancer several chro-
mosomal regions have been described to be frequently
lost[6,11,12], but in most of these regions, no tumour
suppressor genes have been identified yet.
In eukaryote cells, mRNAs molecules that contain prema-
ture termination codons (PTCs) due to nonsense muta-
tions are detected and rapidly degraded by the nonsense-
mediated decay (NMD) mechanism. NMD is mediated
through the assembly of protein complex coded by genes
such as the ones belonging to the UPF family e.g. RENT-1/
UPF1, RENT-2/UPF2, UPF-3A, and UPF-3B[13]. RENT-1/
UPF1 has been shown to play a crucial role in the function
of the NMD system. Taking advantage of the existence of
this regulatory system in the cells, Noensi and Dietz
described a strategy, called GINI (Gene Identification by
Nonsense-mediated decay Inhibition), to identify tumour
suppressor genes harbouring premature stop-codons[14].
Microarrays are used to identify potential nonsense tran-
scripts that are increased in abundance after inhibition of
the NMD system, by comparing the sample to itself after
inhibition of NMD. The NMD pathway can be pharmaco-
logically blocked by treating the cells with a translation
inhibitor, such as emetine, resulting in stabilization of
mutated transcripts containing a premature stop-codon.
However, this drug also induces a stress response resulting
in increased mRNA levels of many transcripts. To more
specifically inhibit the NMD pathway, a different strategy
has been described in which a siRNA directed against
UPF1 is used[15,16].
The combination of NMD microarray data on putative
nonsense mutations with array CGH data on deleted
genomic areas enables the detection of biallelic inactiva-
tion events of tumour suppressor genes, as shown previ-
ously in prostate cancer[17]. Therefore, the present study
aims to identify tumour suppressor genes inactivated by
nonsense mutation and deletion in gastric cancer by
means of GINI and whole genome DNA copy number
analysis.
Methods
Cell lines and cell culture
Two non-commercial gastric cancer cell lines, GP202 and
GP220, established and characterized in IPATIMUP,
Porto[18] were used for siRNA transfection. These partic-
ular cell lines were derived from two different patients and
were not immortalized by viral infection. The cell lines
were maintained in RPMI supplemented with 10% fetal
calf serum, 100 U/mL penicillin, 100 μg/mL streptomycin
and 2 mmol/L L-glutamine (Life Technologies, Breda,
NL).
DNA isolation and Array CGH
Genomic DNA was isolated using TRIzol reagent (Invitro-
gen, Breda, NL) according to the manufacturer's protocol
with some modifications http://www.vumc.com/afdelin
gen/microarrays/. DNA isolated from blood obtained
from eighteen healthy males was pooled and used as nor-
mal reference. DNA concentrations were measured on a
Nanodrop ND-1000 spectrophotometer (Isogen, IJssel-
stein, NL). 500 ng of DNA was labelled using the Enzo
Genomic DNA Labelling kit as described previously (Enzo
Life Sciences, Farmingdale, USA)[19]. Hybridizations
were performed on slides containing four arrays, with
each array containing 45220 in-situ synthesized 60-mer
oligonucleotides, representing 42494 unique chromo-
somal locations (Agilent Technologies, Palo Alto,
USA)[19].
Images of the arrays were acquired using a microarray
scanner G2505B (Agilent technologies) and image analy-
sis was performed using feature extraction software ver-
sion 9.5 (Agilent Technologies,). The Agilent CGH-v4_95
protocol was applied using default settings. Oligonucle-
otides were mapped according to the human genome
build NCBI 35 (May 2004). For both Cy3 and Cy5 chan-
nels, local background was subtracted from the median
intensities. The log2 tumour to normal ratio was calcu-
lated for each spot and normalized against the median of
the ratios of all autosomes.
UPF1 siRNA transfection
Transfection of both cell lines was performed in 35 mm
dishes with 100 nM of siRNA duplexes directed against
UPF1 (Dharmacon, Chicago, IL) or non-specific siRNABMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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duplexes (CVII) (Dharmacon) using the lipofectamine
2000 reagent (Invitrogen) according to the manufacturer's
instructions. Cells were collected for total RNA extraction
72 h after transfection. Each transfection experiment was
performed in duplicate on three different days.
RNA isolation procedures and quantitative real-time PCR
Total RNA was extracted from each cell line using the RNe-
asy kit (Qiagen, Westburg, Leusden, NL) including a
DNase digestion step, according to the manufacturer's
instructions. Concentrations were measured on a Nano-
drop ND-1000 spectrophotometer (Isogen). Synthesis of
cDNA was performed with random primers using the high
capacity cDNA Archive Kit kit (Applied Biosystems). SDS
2.1 Applied Biosystems analysis software was used to
determine the Ct number at which increase in signal is
associated with exponential amplification of the PCR
products, needed to quantify the expression values. Quan-
tification of the 18S ubiquitous RNA was used as the
endogenous reference. The delta Ct was determined in
each case by subtracting the average Ct value of the target
gene from the average Ct value of the 18S gene. The per-
centage of inhibition of the UPF1 gene was calculated by
subtracting the mean delta ct of the UPF1 siRNA trans-
fected cells by the mean delta ct of the CVII siRNA control
transfected cells, as previously described[15].
Microarray expression analysis
Microarray expression experiments were performed on 4 ×
44 K Agilent expression arrays (Agilent technologies) by
hybridizing UPF1 siRNA transfected cells against non-spe-
cific CVII siRNA control transfected cells, according to the
manufacturer's instructions. RNA quality was evaluated
by generating an electropherogram on the Agilent Bioan-
alyzer 2100 using a RNA 6000 Nano-LabChip (Agilent
Technologies). RNA integrity numbers (RIN) of >9.0 were
considered as good quality RNA. Experiments were per-
formed in dye-swap and in triplicate, resulting in six
arrays per cell line. Images of the arrays were acquired
using a microarray scanner G2505B (Agilent technolo-
gies) and image analysis was performed using feature
extraction software version 9.5 (Agilent Technologies).
The Agilent GE2-v5_95 protocol was applied using default
settings.
All data pre-processing and analysis was performed using
the R-Bioconductor package Limma[20]. First, a robust
Edwards background correction was applied, followed by
within-array and between-array normalization using loess
and scale standardization, respectively. Differential
expression between UPF1  siRNA transfected cells and
non-specific CVII siRNA control transfected cells was
assessed by use of a linear model, which accounts for a
blocking factor, the day effect (triplicate). Moreover, the
two-sample t-statistic modified for correlation between
the two duplicates was used. Finally, p-values were
adjusted for multiple testing using convential Benjamini-
Hochberg FDR correction.
Array CGH and microarray expression data can be
assessed using the Gene Expression Omnibus (GEO)
http://www.ncbi.nlm.nih.gov/geo/, under the accession
number GSE12928.
Mutation analysis
From each RNA sample, 1 μg was reverse transcribed to
cDNA using oligo(dT)20 Primer (Invitrogen) with AMV
reverse transcriptase (Promega, Leiden, NL). Mutation
screening involved the entire coding region using primers
overlapping the exon-exon boundaries. Each reaction was
carried out in a total volume of 25 μl containing 1 μl of
cDNA, 1,5 μl MgCl2 (25 mM), 2.5 μl dNTPs (2 mM), 1.25
Units of Amplitaq Gold polymerase (Applied Biosys-
tems), 2.5 μl GeneAmp®10× PCR buffer II and 12.5 pmol
for each forward and reverse primer. When DMSO was
added to the reaction, 2.5 Units of Amplitaq Gold
polymerase was used. Amplification conditions were an
initial denaturation step of 5 minutes at 94°C followed by
40 cycles of 30 seconds at 94°C, 30 seconds at 55–57°C
(depending on the primer pair), 30 seconds at 72°C, and
ending with 7 minutes at 72°C. PCR products were evalu-
ated in a 2% agarose gel. PCR products were purified
using Shrimp Alkaline Posphatase and Exonuclease (SAP
and EXO enzymes) (USB corporation, Cleveland, USA) to
remove the phosphate groups from the excess dNTPs left
over from the PCR reaction and to digest single stranded
PCR primers into dNTPs by incubating for 30 minutes at
37°C, followed by a 15 minute incubation at 80°C to
inactivate the enzymes. Sequence reactions were per-
formed in a total volume of 10 μl containing 3.5 μl puri-
fied PCR product, 2 μl sequencing buffer (5×), 0.5 μl
BigDye Terminater v3.1 mix (Applied Biosystems) and 10
pmol of each forward and reverse primer. Amplification
was performed in 25 cycles of 30 seconds at 96°C, 15 sec-
onds at 45°C and 4 minutes at 60°C. Samples were pre-
cipitated by 0.1 volume NaAc (3 M; pH 5.3) and 2.5
volume ethanol. Sequencing of the PCR products was per-
formed in 10 μl deionised formamide (Applied Biosys-
tems) on an ABI 3130 capillary sequencer (Applied
Biosystems). Sequence analysis was carried out using the
sequence Analysis 5.2 software (Applied Biosystems) and
the Vector NTI software (Invitrogen). Details of the primer
sequences, annealing temperatures and extra PCR condi-
tions are given in Additional file 1.
Genomic DNA sequence analysis was performed with
new designed primers by BaseClear (Leiden, The Nether-
lands).BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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Results
Array CGH profiles
Array CGH profiles of the cell lines GP202 and IPA220
were obtained to detect the deleted areas potentially har-
bouring tumour suppressor genes. Array CGH profiles of
the GP202 and IPA220 gastric cancer cell lines are shown
in figure 1A and 1B, respectively. A detailed overview of all
gains and losses detected in these two cell lines is given in
table 1 and 2.
UPF1 inhibition and expression array analysis
Using the siRNA strategy, UPF1 expression was repressed
by >70% for the GP202 gastric cancer cell line (73% 74%
and 71% for the biological replicates), and >80% for the
IPA220 gastric cancer cell line (82%, 86% and 84% for the
biological replicates).
Micoarray expression array analysis yielded 540 spotted
oligonucleotides significantly upregulated (adjusted p-
values < 0.05) with a log2 ratio > 0.7 in the GP202 cells
transfected with UPF1 siRNA compared to non-specific
CVII siRNA control transfected cells. Of these, 164 oligo-
nucleotides, representing 134 different genes, were
located in deleted areas. The IPA220 UPF1 siRNA trans-
fected cells showed 265 spotted oligonucleotides signifi-
cantly upregulated (adjusted p-values < 0.05) with a log2
ratio > 0.7 compared to non-specific CVII siRNA control
transfected cells. Of these, 50 different genes were located
in deleted areas. Of these genes, we selected genes with
only one known transcript according to ensemble http://
www.ensembl.org/Homo_sapiens/index.html and genes
of which no alternative splice patterns were known. This
yielded a list of 10 candidate genes to be inactivated by
nonsense mutation and deletion. The genes PLA2G4A,
BMP5, MMP6, KNNMB4 and DYM were candidates for
the GP202 gastric cancer cell line and the genes TXNL4B,
FOXK1, PTPRJ, and SNN were candidates for the IPA220
gastric cancer cell line. The gene SLITRK6 was selected as
a candidate gene for both gastric cancer cell lines, however
only in the GP202 gastric cancer cell line this gene was
located in a deleted area. In addition we selected two
genes potentially inactivated by nonsense mutation
which were located outside deleted areas, but showed
high log2 ratios and no known splice variants (CSTA for
the GP202 and INHBB for the IPA220 gastric cancer cell
lines). Candidate genes, including their chromosomal
location are presented in Table 3.
Mutation analysis
Of the 12 candidate genes, we successfully completed
sequence analysis of 11 genes. After complete sequencing,
KCNMB4, BMP5, DYM, TXNL4B, and SNN did not show
any mutation. SLITRK6 did not show a mutation in the
UPF1 siRNA-transfected IPA220 and GP202 gastric cancer
cells. However, in the UPF1 siRNA-transfected GP202 gas-
tric cancer cells, the first 196 bp of the coding sequence
was missing due to PCR failures. For the gene INHBB the
first 413 bp of the coding sequence was missing due to
PCR failures but no mutation was detected in the remain-
ing coding sequence. Due to the PCR failures, sequence
analysis of these two genes was also performed on
genomic DNA with new designed primers (BaseClear, Lei-
den, The Netherlands). Although sequencing of SLITRK6
was successfully performed, no mutations were detected
in this gene. Sequencing the genomic DNA of the gene
INHBB  was unsuccessful, consistent with the cDNA
sequence of the gene.
In CSTA a heterozygous mutation was detected in both
GP202 and IPA220 gastric cancer cells transfected with
UPF1 siRNA, at position 298 (mRNA seq. NM005213.3)
resulting in a G to C substitution, which in turn resulted
in an amino acid change from GTA (Valine) to a ATA (Iso-
leucine) at position 57 of the CSTA protein. In PLA2G4A,
a mutation was detected in the UPF1 siRNA-transfected
GP202 gastric cancer cells, at position 1012 (mRNA seq
NM_024420.1) resulting in a C to T substitution at posi-
tion 303 of the protein, but this mutation did not result in
a different amino acid (GAC to GAT (Aspartate)). In
PTPRJ, three mutations were detected in the UPF1 siRNA-
transfected IPA220 gastric cancer cells. The first mutation
resulted in a C to A substitution at position 1183 (mRNA
seq NM_002843.3), which resulted in a CAA (glutamine)
to CCA (proline) amino acid change at position 276 of
the PTPRJ protein. The second mutation resulted in a G to
A substitution at position 1333 (mRNA seq NM-
002843.3), resulting in an amino acid change from CGA
(Arginine) to CAA (Glutamine) at position 326 of the pro-
tein. The last mutation resulted in a G to C substitution at
position 2972 (mRNA seq (NM_002843.3), resulting in
CAG (Glutamine) to GAC (Aspartate) amino acid change
at position 836 of the protein (Figure 2). Only the last
mutation was detected in the GP202 gastric cancer cells
transfected with UPF1 siRNA, but this was a heterozygous
mutation.
Using the first primer set of MPP6, two bands were
detected on the gel. After sequencing both bands we
observed a 33 bp deletion before the coding start site in
the shorter band which is suggestive for a splice variant
since the exon-exon boundary is involved (Figure 3). No
mutations were detected. An overview of the mutations
detected in this study is presented in table 4.
Discussion
Gastric cancer is a major cause of cancer death, but knowl-
edge about the biology underlying gastric cancer develop-
ment is still limited. Several chromosomal regions have
been described to be frequently deleted in gastric cancer,
but in most of the regions, no tumour suppressor genesBMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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DNA copy number profile obtained by array CGH analysis of the GP202 gastric cancer cell line Figure 1
DNA copy number profile obtained by array CGH analysis of the GP202 gastric cancer cell line. (A) and the 
IPA220 gastric cancer cell line (B). Normalised log2 tumour to normal ratios of every spot are presented sorted by posi-
tion in chromosomal order (1-Y). Dashed-vertical lines – transition between the chromosomes.BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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Table 1: Overview of all chromosomal gains and losses detected in the gastric cancer cell line GP202
Gains Losses
Cytoband Start (bp) Segment size (Mb) Cytoband Start (bp) Segment size (Mb)
1p36.33-1p36.32 604268 3.10
1p36.21-1p35.1 14554092 18.26
1p32.3-1p31.2 51415638 17.20
1p31.1-1p31.1 75490653 3.21
1p31.1-1p22.3 84414481 2.76
1p22.2-1p13.3 91093183 19.83
1q24.3-1q44 167792143 77.63
2p25.3-2p23.3 29193 24.75
2p23.1-2p22.2 30171297 7.64
2p22.2-2p22.1 38068378 1.57
2p22.1-2p21 39804095 2.17
2p21-2p21 42322892 1.85
2p21-2p16.2 44568947 8.24
2p12-2p12 75641228 7.06
2q14.1-2q14.1 114390667 2.40
2q24.1-2q24.1 155514824 1.07
2q24.3-2q24.3 166690618 1.25
2q32.1-2q32.2 184949202 4.73
3p26.3-3p11.1 224727 87.69
3q11.2-3q11.2 95295727 3.77
3q12.1-3q12.2 100024301 1.70
3q22.3-3q24 140145815 8.85
3q24-3q25.1 149729642 3.28
3q25.2-3q26.1 156397505 6.15
3q26.1-3q26.1 162557800 6.25
3q26.2-3q26.31 170346051 4.88
3q26.32-3q29 177640401 20.35
4p16.3-4q35.2 62447 191.20
5p15.33-5p14.1 148243 29.04
5p13.3-5p12 30636882 13.08
5q11.2-5q12.1 50714334 8.21
5q12.3-5q14.2 65345185 17.43
5q31.3-5q31.3 143269803 1.01
5q33.3-5q34 158674495 4.67
6p21.2-6p21.2 38554812 0.15
6p12.1-6p12.1 54055870 2.14
6p11.2-6q13 58122432 12.68
6q15-6q16.1 91282705 5.81
6q16.3-6q21 101156415 4.21
6q24.3-6q24.3 147629943 0.12
6q25.2-6q25.3 155542493 0.97
6q25.3-6q27 156677778 14.13
7p21.3-7p14.1 8408484 33.10
7p11.2-7p11.2 54921296 0.57
7q11.21-7q11.22 65833193 4.96
7q11.23-7q11.23 76818583 0.16
7q21.13-7q31.1 90482514 19.64
7q31.1-7q31.1 110637986 1.28
7q31.1-7q31.2 113074003 2.15
7q31.33-7q31.33 124912671 0.76
7q34-7q35 142863066 0.23
7q35-7q36.3 147112584 11.48
8p23.3-8p23.1 181530 11.15
8p23.1-8p11.21 12627630 29.40
8p11.21-8q21.3 42137357 49.48
8q22.1-8q22.3 95005574 9.49
8q24.11-8q24.3 117851748 28.40BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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9p24.3-9p24.2 204367 3.94
9p23-9p22.3 9335062 5.76
9p21.1-9p21.1 28203365 2.53
9q13-9q21.13 68264900 4.61
9q21.13-9q21.31 74400503 5.06
9q21.33-9q22.1 85372508 2.87
9q22.2-9q22.31 89232280 2.91
9q22.31-9q22.32 93160028 1.30
9q22.33-9q31.1 97586481 3.58
9q31.1-9q31.1 104314825 0.46
9q31.3-9q32 110265680 3.46
9q33.1-9q33.2 115059550 7.40
9q33.2-9q33.3 122895073 0.42
9q33.3-9q34.11 126436029 3.69
10p15.3-10p11.22 138206 34.13
10q21.1-10q26.3 54480789 80.81
11p11.2-11p11.2 43422214 1.84
11q12.1-11q13.4 57256449 13.13
11q14.3-11q14.3 87970040 0.76
11q14.3-11q14.3 89525497 0.05
11q21-11q22.1 96058479 3.39
12q12-12q22 37052371 55.79
12q23.1-12q23.3 96894351 6.93
12q24.23-12q24.23 117761811 0.61
12q24.31-12q24.31 121971290 1.03
12q24.31-12q24.33 123020939 9.36
13q12.2-13q13.1 27392825 5.14
13q13.3-13q21.33 34631933 36.49
13q31.1-13q31.3 79911534 13.43
14q11.2-14q11.2 19365051 2.79
14q11.2-14q12 22545671 6.72
14q13.3-14q21.1 36741208 0.35
14q21.1-14q21.2 40137052 3.71
14q21.2-14q21.3 45739681 3.13
14q31.1-14q32.33 78503451 27.83
15q11.2-15q24.1 19109124 52.29
15q24.1-15q26.3 71444303 28.72
16p13.3-16p13.3 1339391 3.35
16p13.3-16p12.3 5565717 13.83
16p12.3-16p12.3 19426488 0.04
16p12.3-16q21 19493912 38.95
16q22.1-16q22.1 66730760 1.00
16q22.1-16q23.1 67757442 9.01
16q23.1-16q24.3 77573211 11.08
17p13.3-17p13.1 48539 7.48
17q11.1-17q11.2 22335103 1.75
18p11.32-18q12.1 170229 30.01
18q12.3-18q23 36319629 39.76
19p13.3-19q12 232080 33.93
19q12-19q13.31 36336102 12.74
19q13.32-19q13.32 52132977 0.56
20p13-20p12.1 18580 14.51
20p12.1-20p12.1 14772372 1.30
20p11.21-20q13.33 24262140 38.10
21q21.1-21q21.3 17434961 11.95
21q21.3-21q22.3 29452714 16.38
Table 1: Overview of all chromosomal gains and losses detected in the gastric cancer cell line GP202 (Continued)BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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Table 2: Overview of all chromosomal gains and losses detected in the gastric cancer cell line IPA220.
Gains Losses
Cytoband Start (bp) Segment size (Mb) Cytoband Start (bp) Segment size (Mb)
1p33-1p36.33 1532086 45.95
1p33-1p33 48905659 0.05
1p22.3-1p22.3 85435027 0.06
2q22.1-2q11.1 95057834 45.61
2q33.1-2q33.1 200167066 0.43
3p26.3-3p22.1 224727 40.68
4p16.3-4p16.3 62447 1.83
4q13.3-4q13.1 60036497 14.87
5p12-5p15.33 148243 43.37
5q33.2-5q31.3 141986337 12.82
6p25.3-6p25.3 204528 0.03
6p12.3-6p21.1 43716420 5.79
6q12-6p12.1 56790132 12.18
6q27-6q14.1 80423355 90.39
7p22.3-7p22.1 149268 4.55
7p21.1-7p22.1 4874872 14.88
7q34-7p12.1 53246250 86.37
8p23.3-8p11.21 181530 42.99
8q24.3-8q11.1 47062121 99.19
9q34.2-9q34.3 133008166 5.28
10p15.3-10p13 138206 16.20
10p12.33-10p13 16543648 1.39
10q11.22-10p11.22 33177446 13.39
10q11.23-10q11.23 51219561 0.04
10q21.1-10q22.1 53701099 18.43
10q22.1-10q22.1 74316662 0.24
10q22.1-10q22.2 74569446 0.95
10q22.2-10q22.2 75567726 0.57
10q22.2-10q22.2 76194936 0.41
10q22.2-10q24.2 77212707 23.02
10q26.3-10q26.3 133641790 1.65
11p14.1-11p15.5 2389958 27.82
11p12-11p11.12 39023903 11.61
11q13.1-11q13.1 65527252 0.02
11q14.3-11q14.3 88320337 0.38
11q22.3-11q23.3 103942362 13.29
11q23.3-11q25 117574530 16.38
12p13.33-12p13.33 1471571 0.32
13q21.31-13q12.13 24807238 37.57
14q24.3-14q24.3 74237320 1.26
14q32.33-14q32.33 103705675 2.24
16p13.3-16p13.3 258880 1.09
16q12.2-16q12.1 48880404 2.95
16q12.2-16q22.1 53523174 12.50
16q22.1-16q24.3 66132070 22.52
17q21.31-17q21.31 41566540 0.06
18q11.2-18p11.22 10662792 7.80
18q11.2-18q11.2 20896260 0.38
18q23-18q11.2 21531881 53.70
18q23-18q23 75803559 0.28
19p13.3-19p13.3 232080 0.75
19q13.12-19q12 34074193 6.56
20p11.21-20p11.22 21329267 4.35
20q13.33-20q11.21 29352138 33.01
21q21.1-21q11.2 13926078 6.84
21q22.3-21q22.3 45354820 1.07
22q11.22-22q11.1 14433473 7.35
22q12.1-22q11.23 23692593 2.23
22q12.1-22q13.1 26016519 10.56
22q13.1-22q13.1 37683612 0.03
22q13.33-22q13.31 44867938 3.71BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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have been described yet. Using the GINI strategy in com-
bination with array CGH, we aimed to identify tumour
suppressor genes inactivated by nonsense mutation and
deletion in gastric cancer cell lines.
The first GINI strategies used a translation inhibitor to
block the NMD pathway. By using translation inhibitors,
the half-lives of many mRNAs are increased making it dif-
ficult to identify genes of which mRNA is increased due to
the existence of a PTC[21]. In an attempt to improve
detection of changes in decay rates, actinomycin D treat-
ment, which stops initiation of mRNA synthesis, has been
combined with translation inhibitors[17]. This strategy
proved not to be as efficient as initially thought, probably
due to side-effects of the drugs which have been suggested
to include stabilization of the transcriptome, resulting in
protection of the transcripts from degradation. In addi-
tion, using drug treatment, an overall stress response is
induced resulting in upregulation of many tran-
scripts[21,22]. We have previously used a combination of
emitine and actinomycin D treatment to inhibit the NMD
machinery in three colorectal cancer cell lines, two micro-
satellite stable (HT29 and colo205) and one microsatel-
lite instable (RKO). Sequence analysis of the candidate
genes did not lead to the identification of any truncation
mutation (data not shown).
In the present study, we used siRNAs directly targeting
UPF1 which plays a central role in the NMD machinery.
This approach was thought to result in less false positive
genes compared to chemical translation inhibi-
tors[15,22]. However, as the present study indicated, in
our hands this method also resulted in multiple false pos-
itive candidate genes.
Nonetheless, the GINI approach, using drug translation
inhibitors in combination with transcription blockers,
has been successfully applied in prostate and colon cancer
cell lines[17,23]. Also a different GINI approach (GINI2),
using caffeine for NMD inhibition, has been successfully
applied in the identification of bi-allelic inactivating
mutations[24]. Blocking the NMD machinery using the
siRNA strategy was also successful in detecting genes car-
rying PTCs in colorectal cancer cell lines[15]. However, in
all these studies only cancer cell lines with microsatellite
instability were analyzed, increasing the chance of success
as microsatellite instable cell lines present, due to their
phenotype, a high frequency of frameshift mutations
leading to PTCs. To our knowledge, this is the first study
describing the GINI technology in microsatellite stable
gastric cancer cell lines blocking the NMD mechanism by
siRNAs targeting UPF1. After sequencing the mRNA tran-
scripts of the putative candidate genes, we did not detect
nonsense mutations. The fact that the cell lines used in
this study are not microsatellite instable may justify the
lack of success on finding genes harbouring premature
PTCs. However, the technique should also be applicable
on microsatellite stable cancer cell lines as shown by
Pinyol et al[25]. In their study, five mantle cell lymphoma
cell lines were examined which may result in a more accu-
rate and stringent selection of candidate genes compared
to our data analysis in which we only used two cell lines.
Although no nonsense mutations were found in this
study, we did detect silent or missense mutations in three
genes. A silent mutation was detected in the gene
PLA2G4A at position 303 of the protein. This polymor-
phism has not been previously described. A missense
mutation was detected in the CTSA gene at position 57 of
the protein changing a Valine into an Isoleucine. In the
gene PTPRJ, three missense mutations were detected in
IPA220 gastric cancer cell line. The mutations Gln276Pro
and Arg326Gln in exons 5 and 6, respectively, have been
described before as being polymorphisms[26]. To our
knowledge, the third mutation, Glu836Asp, in exon 13,
has not been previously described, thus the biological
consequence, if any, is not clear. Loss of heterozygosity
(LOH) of PTPRJ has been detected in breast, lung and
Table 3: List of 12 candidate genes putatively inactivated by nonsense mutation, including their chromosomal location, the cell line 
where it was identified and a short description of the gene.
Gene Location Cell line Description
PLA2G4A 1q31.1 GP202 phospholipase A2, group IVA
INHBB 2q14,2 IPA220 Inhibin, beta B
CSTA 3q21.1 GP202 Cystatin A
BMP5 6p12.1 GP202 Bone morphogenetic protein 5
MMP6 7p15.3 GP202 membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6)
FOXK1 7p22.1 IPA220 Forkhead box K1
PTPRJ 11p11.2 IPA220 Protein tyrosine phosphatase, receptor type J
KCNMB4 12q15 GP202 Potassium channel, calcium-activated, large conductance, subfamily M, beta member 4
SLITRK6 13q31.1 GP202, IPA220 SLIT and NTRK-like family, member 6
SNN 16p13 IPA220 stannin
TXNL4B 16q22.2 IPA220 Thioredoxin-like 4B
DYM 18q21.1 GP202 dymecelinBMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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Mutations analysis of PTPRJ in the IPA220 siRNA transfected cells yielded three polymorphisms, A1183C on exon 5 (A),  G1333A on exon 6 (B) and G2972C on exon 13 (C) Figure 2
Mutations analysis of PTPRJ in the IPA220 siRNA transfected cells yielded three polymorphisms, A1183C on 
exon 5 (A), G1333A on exon 6 (B) and G2972C on exon 13 (C).
First part of the mRNA sequence of the MMP6 gene Figure 3
First part of the mRNA sequence of the MMP6 gene. The sequence in bold represents the missing sequence in the 
smaller PCR product, located upstream of the start codon. Bold and underlined nucleotides represent the exon-exon bounda-
ries The start codon ATG is indicated in bold and italic.BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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colon cancers and expression has been shown to induce
differentiation and to inhibit growth of breast cancer cells,
indicating a function as tumour suppressor gene [26-28].
Since we detected missense mutations of this gene in the
gastric cancer cell lines analyzed, it gives the indication
that PTPRJ might play a role as tumour suppressor gene in
gastric cancer, however, apparently not by inactivation by
nonsense mutation.
One explanation why our strategy of GINI combined with
DNA copy number profiling failed to detect new tumour
suppressor genes with nonsense mutations could be that
these nonsense mutations are less common than
expected. Indeed, recent massive sequencing studies have
identified that many cancer related genes often are
mutated in only low frequencies, while alternative mech-
anisms of inactivation like promoter hypermethylation
are much more common[29,30].
An important point is why siRNA inhibition of UPF1 gen-
erates so many false positive hits. Besides a crucial role of
UPF1 in RNA degradation pathways, the gene also plays a
role in DNA replication during the S phase of the cell
cycle, and has been shown to be involved in DNA metab-
olism. UPF1 depletion causes cells to arrest in the S phase
and those cells are able to initiate but not complete DNA
replication. UPF1 depleted cells have been shown to har-
bour increased chromatid and chromosome breaks lead-
ing to chromosomal aberrations[31,32]. In addition,
UPF1 has been shown to promote the rate and efficiency
of translation of normal mRNAs in mammalian cells[33].
Translation termination in UPF1 mutants was shown to
be dependent on the sequence context. Efficient transla-
tion termination was observed when UCC (Serine) was
located upstream and GCA (Alanine) was located down-
stream of the PTC. Location of CAA (Glutamine) on either
side of the PTC resulted in up to 100 fold reduction in effi-
ciency of translation termination[34]. We could speculate
that by inhibiting UPF1 by siRNAs also mRNAs without
PTCs are not efficiently translated into proteins, and con-
sequently negative feedback loops are not activated, caus-
ing the cell to produce more mRNAs due to lack of
functional proteins essential for the cell. This in turn can
cause accumulation of mRNA resulting in false positive
genes. Another hypothesis possibly contributing to the
false positive genes found in our analysis can involve the
coding sequence surrounding the PTCs which can deter-
mine the efficiency of the NMD machinery. Also, NMD
downregulates wild-type transcripts and regulates the
expression of many physiological transcripts[16]. Physio-
logical substrates for NMD include transcripts with alter-
native splice variants. For this reason we excluded the
genes with multiple known splice variants as candidate
genes carrying a PTC, thereby limiting the rate of false pos-
itive candidate genes. Nonetheless, among the genes with
one known transcript, the GINI technology still yielded
many false positive candidate genes.
Finally, although 70–80% depletion of UPF1 is thought
to be sufficient for inhibiting the NMD machinery both in
microsatellite instable cell lines[15] as well as in microsat-
ellite stable gastric cancer cell lines[35], with correlation
with downregulation of the UPF1 protein, we cannot
exclude the possibility that in this case the treatment was
insufficient.
Despite the fact that we did not successfully detect genes
carrying a PTC using the GINI technology, we cannot rule
out that the gene INHBB did not harbour a PTC since we
were unable to sequence the full length of the gene. How-
ever, all other candidate genes were successfully
sequenced without detecting a PTC. Therefore, we still
believe that the siRNA mediated inhibition of the NMD
machinery yields many false positive candidate genes.
In summary, we aimed to find candidate genes inactivated
by nonsense mutation and deletion in the gastric cancer
cell lines to further validate our results of DNA copy
number profiling and expression analysis in primary gas-
tric cancers. Although the GINI technology theoretically is
a powerful method for identifying candidate tumour sup-
pressor genes inactivated by nonsense mutations, siRNA
mediated inhibition of the NMD machinery yielded false
positive results in our hands. The GINI technique might
be optimized by using a vector containing multiple small
hairpin RNAs (shRNAs) that can silence multiple target
sites simultaneously, to more effectively knockdown the
NMD system[36]. Moreover, applying this strategy on
Table 4: Overview of mutations detected in the candidate genes
Gene Nucleotide Amino acid Exon
CSTA G298C Val57Ile 2
PLA2G4A C1012T Asp303Asp 15
PTPRJ A1183C Gln276Pro 5
G1333A Arg326Gln 6
G2972C Glu836Asp 13BMC Medical Genomics 2009, 2:39 http://www.biomedcentral.com/1755-8794/2/39
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multiple cell lines might be a more conservative approach
applicable for selecting candidate genes, thereby contrib-
uting to less false positive test results. On the other hand,
the discovery of new tumour suppressor genes inactivated
by nonsense mutation by means of GINI may be redun-
dant in the near future due to the emerging of the next-
generation technologies in which the complete genome
can be analyzed by massive parallel sequencing[37].
Conclusion
The GINI technology by means of siRNA mediated inhibi-
tion of the NMD machinery in gastric cancer cell lines
yielded false positive results in our hands.
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